Departments of Medicine and Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19010, USA.
Clin Cancer Res. 2012 Apr 1;18(7):1827-9. doi: 10.1158/1078-0432.CCR-12-0153. Epub 2012 Mar 26.
Over the past 5 years, patients with progressive radioactive iodine-refractory thyroid cancer have responded to "targeted" multikinase inhibitors, which inhibit angiogenesis and not the tumor cell. Here, selumetinib targets the mitogen-activated protein kinase pathway in papillary thyroid carcinoma and shows limited single-agent activity in the patients with tumors that harbor the (V600E)BRAF mutation.
在过去的 5 年中，患有进行性放射性碘难治性甲状腺癌的患者对“靶向”多激酶抑制剂有反应，这些抑制剂抑制血管生成而不是肿瘤细胞。在这里，selumetinib 靶向甲状腺乳头状癌中的丝裂原活化蛋白激酶途径，并且在携带 (V600E)BRAF 突变的肿瘤患者中具有有限的单药活性。
